SGLT-2 Inhibition, Metabolomics and Cardiovascular/Kidney Disease
NCT03919656
·
clinicaltrials.gov ↗
PHASE4
Phase
COMPLETED
Status
60
Enrollment
OTHER
Sponsor class
Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG:
Dapagliflozin 10 mg
DRUG:
Placebo Oral Tablet
Sponsor
Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud